ARS Pharmaceuticals (SPRY) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg.
The phase 3 trial of the nasal spray in Japanese patients aged 6 to 17, who had anaphylactic symptoms after food, had a 100% success rate in removing symptoms in about 16 minutes, the company said Thursday in a statement.
Additional tests in China matched US studies with similar results, the company said.
The treatment is approved in the US for severe allergic reactions.
Price: 12.50, Change: +0.23, Percent Change: +1.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments